Active — Not RecruitingNot Applicable

Infliximab Infusion Rates in Pediatric Inflammatory Bowel Disease

Norway60 participantsStarted 2025-02-01

Plain-language summary

OBJECTIVES OF THE STUDY 1. Investigate whether there are just as few infusion reactions with infliximab infusions of 60 min and 30 min. 2. Investigate patient and nurse satisfaction with infusions of 60 min and 30 min. 3. Investigate resource use in terms of total length of stay and use of nursing resources.

Who can participate

Age range1 Year – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pediatric IBD patients on infliximab * 1-17 years * Received at least 5 infusions of infliximab prior to entry in the study Exclusion Criteria: * Receiving infliximab for non-IBD condition (reumatological or other causes) * previous severe infliximab infusion reaction * need for an interpreter * heart failure with hemodynamic impact * unwillingness to participate

What they're measuring

Number of infusion reactions with infliximab infusions given over 60 minutes compared to 30 minutes.

Timeframe: depending on patients infusion intervals; 4 weeks x8 = 32 weeks, 8 weeks interval x8 = 64 weeks. The estimated time frame to complete the study for all included patients is april 2026.

Trial details

NCT IDNCT06839820

SponsorUniversity Hospital, Akershus

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

View on ClinicalTrials.gov More Infliximab trials